Ontology highlight
ABSTRACT:
SUBMITTER: Mehnert JM
PROVIDER: S-EPMC6013351 | biostudies-literature | 2018 Jul
REPOSITORIES: biostudies-literature
Mehnert Janice M JM Silk Ann W AW Lee J H JH Dudek Liesel L Jeong Byeong-Seon BS Li Jiadong J Schenkel Jason M JM Sadimin Evita E Kane Michael M Lin Hongxia H Shih Weichung J WJ Zloza Andrew A Chen Suzie S Goydos James S JS Goydos James S JS
Pigment cell & melanoma research 20180410 4
Studies demonstrate that GRM, expressed by >60% of human melanomas, may be a therapeutic target. We performed a phase II trial of 100 mg PO bid of riluzole, an inhibitor of GRM1 signaling, in patients with advanced melanoma with the primary endpoint of response rate. Thirteen patients with GRM1-positive tumors were enrolled. No objective responses were observed, and accrual was stopped. Stable disease was noted in six (46%) patients, with one patient on study for 42 weeks. Riluzole was well tole ...[more]